FDA Grants Arrowhead (ARWR) Clearance to Initiate Adipotide Phase I Clinical Trial
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Join SI Premium – FREE
Arrowhead Research Corporation (NASDAQ: ARWR) today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound. Adipotide specifically targets and kills blood vessels supplying white fat tissue. The Phase I clinical trial will be conducted by The University of Texas MD Anderson Cancer Center, which will bear the costs of the planned clinical trial.
“This is a significant milestone for our rapidly moving obesity program,” said Dr. Christopher Anzalone, President and Chief Executive Officer. “Less than two months ago, data demonstrating substantial weight loss in obese rhesus monkeys using AdipotideTM was published in the prominent peer-reviewed journal, Science Translational Medicine. We are very excited to take this next step and that MD Anderson plans to start treating patients shortly. We believe we have a powerful suite of drug candidates that not only may help to combat obesity, but also may help to reverse symptoms associated with Type II Diabetes.”
“This is a significant milestone for our rapidly moving obesity program,” said Dr. Christopher Anzalone, President and Chief Executive Officer. “Less than two months ago, data demonstrating substantial weight loss in obese rhesus monkeys using AdipotideTM was published in the prominent peer-reviewed journal, Science Translational Medicine. We are very excited to take this next step and that MD Anderson plans to start treating patients shortly. We believe we have a powerful suite of drug candidates that not only may help to combat obesity, but also may help to reverse symptoms associated with Type II Diabetes.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
- Harrow study shows Iheezo cuts discomfort after eye injections
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
